Literature DB >> 24971478

ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.

Simon Shek-Man Lo1, Elizabeth M Gore, Jeffrey D Bradley, John M Buatti, Isabelle Germano, A Paiman Ghafoori, Mark A Henderson, Gregory J A Murad, Roy A Patchell, Samir H Patel, Jared R Robbins, H Ian Robins, Andrew D Vassil, Franz J Wippold, Michael J Yunes, Gregory M M Videtic.   

Abstract

Pretreatment evaluation is performed to determine the number, location, and size of the brain metastases and magnetic resonance imaging (MRI) is the recommended imaging technique, particularly in patients being considered for surgery or stereotactic radiosurgery. A contiguous thin-cut volumetric MRI with gadolinium with newer gadolinium-based agents can improve detection of small brain metastases. A systemic workup and medical evaluation are important, given that subsequent treatment for the brain metastases will also depend on the extent of the extracranial disease and on the age and performance status of the patient. Patients with hydrocephalus or impending brain herniation should be started on high doses of corticosteroids and evaluated for possible neurosurgical intervention. Patients with moderate symptoms should receive approximately 4-8 mg/d of dexamethasone in divided doses. The routine use of corticosteroids in patients without neurologic symptoms is not necessary. There is no proven benefit of anticonvulsants in patient without seizures. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Entities:  

Mesh:

Year:  2014        PMID: 24971478      PMCID: PMC4275774          DOI: 10.1089/jpm.2014.9417

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  37 in total

1.  Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  M J Glantz; B F Cole; P A Forsyth; L D Recht; P Y Wen; M C Chamberlain; S A Grossman; J G Cairncross
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Imaging patterns of multifocal gliomas.

Authors:  A P Kyritsis; V A Levin; W K Yung; N E Leeds
Journal:  Eur J Radiol       Date:  1993-04       Impact factor: 3.528

3.  Computed tomographic scanning of the brain in initial staging of bronchogenic carcinoma.

Authors:  R G Hooper; M F Tenholder; G H Underwood; C R Beechler; L Spratling
Journal:  Chest       Date:  1984-06       Impact factor: 9.410

4.  Use of 3.0-T MRI for stereotactic radiosurgery planning for treatment of brain metastases: a single-institution retrospective review.

Authors:  Paul A Saconn; Edward G Shaw; Michael D Chan; Sarah E Squire; Annette J Johnson; Kevin P McMullen; Stephen B Tatter; Thomas L Ellis; James Lovato; J Daniel Bourland; Kenneth E Ekstrand; Allan F DeGuzman; Michael T Munley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-09       Impact factor: 7.038

5.  Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?

Authors:  Christina Hempen; Elisabeth Weiss; Clemens F Hess
Journal:  Support Care Cancer       Date:  2002-02-09       Impact factor: 3.603

6.  Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer.

Authors:  D Ferrigno; G Buccheri
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

7.  Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.

Authors:  M Z Papa; J T Vetto; S E Ettinghausen; J J Mulé; S A Rosenberg
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

8.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

9.  Cerebral lesions incidentally detected on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies.

Authors:  Vinicius Ludwig; Tsuyoshi Komori; David Kolb; William H Martin; Martin P Sandler; Dominique Delbeke
Journal:  Mol Imaging Biol       Date:  2002-10       Impact factor: 3.488

10.  Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.

Authors:  W T Yuh; D J Fisher; V M Runge; S W Atlas; S E Harms; K R Maravilla; N A Mayr; J E Mollman; A C Price
Journal:  AJNR Am J Neuroradiol       Date:  1994-06       Impact factor: 3.825

View more
  8 in total

1.  Corticosteroids for peritumoral edema: time to overcome our addiction?

Authors:  Eudocia Q Lee; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08-16       Impact factor: 12.300

2.  MRI-based radiosurgical planning: implications in imaging timing.

Authors:  William C Stross; Timothy D Malouff; Daniel M Trifiletti; Laura A Vallow
Journal:  Ann Transl Med       Date:  2019-09

Review 3.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

4.  The Infratentorial Localization of Brain Metastases May Correlate with Specific Clinical Characteristics and Portend Worse Outcomes Based on Voxel-Wise Mapping.

Authors:  Zhangqi Dou; Jiawei Wu; Hemmings Wu; Qian Yu; Feng Yan; Biao Jiang; Baizhou Li; Jinghong Xu; Qi Xie; Chenguang Li; Chongran Sun; Gao Chen
Journal:  Cancers (Basel)       Date:  2021-01-17       Impact factor: 6.639

5.  Comparison of survival outcomes after CyberKnife® radiotherapy in Taiwan using preapproved insurance-based reimbursement versus out-of-pocket expenditure.

Authors:  Ya-Hui Hsu; Mei-Yueh Huang; Chin-Ju Huang; Hui-Hua Kao; Yu-Jie Huang
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

6.  Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Authors:  Pierpaolo Pastina; Valerio Nardone; Cirino Botta; Stefania Croci; Paolo Tini; Giuseppe Battaglia; Veronica Ricci; Maria Grazia Cusi; Claudia Gandolfo; Gabriella Misso; Silvia Zappavigna; Michele Caraglia; Antonio Giordano; Donatella Aldinucci; Pierfrancesco Tassone; Pierosandro Tagliaferri; Luigi Pirtoli; Pierpaolo Correale
Journal:  Oncotarget       Date:  2017-08-24

7.  The Effect of Slice Thickness on Contours of Brain Metastases for Stereotactic Radiosurgery.

Authors:  Sara L Thrower; Karine A Al Feghali; Dershan Luo; Ian Paddick; Ping Hou; Tina Briere; Jing Li; Mary Frances McAleer; Susan L McGovern; Kristina Demas Woodhouse; Debra Nana Yeboa; Kristy K Brock; Caroline Chung
Journal:  Adv Radiat Oncol       Date:  2021-04-11

Review 8.  Imaging of Oligometastatic Disease.

Authors:  Naik Vietti Violi; Rami Hajri; Laura Haefliger; Marie Nicod-Lalonde; Nicolas Villard; Clarisse Dromain
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.